Peptides with antioxidant and antimicrobial properties

Abstract

One embodiment of the present invention is directed toward methods for inhibiting the oxidation of lipids, proteins, and other compounds. Another embodiment is directed toward methods for treating conditions associated with microbial contamination, colonization, and/or infection.

1 . A method of treating conditions associated with lipid oxidation, comprising the step of administering to a mammal a composition comprising a pharmacologically effective amount of an antioxidant lung surfactant protein compound.  
     
     
         2 . A method according to  claim 1 , wherein the antioxidant lung surfactant protein compound is selected from the group consisting of surfactant protein A and derivatives, analogs, homologs, salts and fragments thereof; surfactant protein D and derivatives, analogs, homologs, salts and fragments thereof; and mixtures thereof.  
     
     
         3 . A method according to  claim 1 , wherein the antioxidant lung surfactant protein compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 2-17.  
     
     
         4 . A method according to  claim 1 , wherein the antioxidant lung surfactant protein compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 4-6, and 9-17.  
     
     
         5 . A method according to  claim 4 , wherein the antioxidant lung surfactant protein compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 5-6, 10-11, and 16-17.  
     
     
         6 . A method according to  claim 3 , wherein the composition further comprises a lipophilic compound selected from the group consisting of organic solvents, phosphatidyl cholines, cholesterols and mixtures thereof.  
     
     
         7 . A method according to  claim 1 , wherein the step of administering is a dosing method selected from the group consisting of oral administering, parenteral administering, transdermal administering, subcutaneous injecting, intravenous injecting, intraperitoneal injecting, intramuscular injecting, intrasternal injection, intrathecal injection, intraventricular injecting, intracerebroventricular injecting, and infusing.  
     
     
         8 . A method according to  claim 1 , wherein the composition is administered in a unitary dose of from about 1 mg to about 1000 mg.  
     
     
         9 . A method according to  claim 8 , wherein the unitary dose is administered from about 1 to about 3 times a day.  
     
     
         10 . A method of treating a patient for acute lung injury comprising administering to the patient an effective antioxidation amount of an antioxidant lung surfactant protein compound selected from the group consisting of surfactant protein A and derivatives, analogs, homologs, salts, and fragments thereof; surfactant protein D and derivatives, analogs, homologs, salts, and fragments thereof; and mixtures thereof.  
     
     
         11 . A method of treating a patient for atherosclerosis comprising administering to the patient an effective antioxidation amount of the antioxidant lung surfactant protein of  claim 2 .  
     
     
         12 - 26 . (canceled)  
     
     
         27 . A method of inhibiting or reducing microbial contamination, colonization or infection, comprising the step of administering to a mammal a composition comprising a hydrophilic antimicrobial effective amount of an antimicrobial lung surfactant protein compound.  
     
     
         28 . A method according to  claim 27 , wherein the antimicrobial lung surfactant protein compound is selected from the group consisting of surfactant protein A and derivatives, analogs, homologs, salts, and fragments thereof; surfactant protein D and derivatives, analogs, homologs, salts, and fragments thereof; and mixtures thereof.  
     
     
         29 . A method according to  claim 27 , wherein the antimicrobial lung surfactant proteing compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1-17.  
     
     
         30 . A method according to  claim 27 , wherein the antimicrobial lung surfactant protein compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 4-6, and 9-17.  
     
     
         31 . A method according to  claim 30 , wherein the antimicrobial lung surfactant protein compound has an amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 5-6, 10-11, and 16-17.  
     
     
         32 . A method according to  claim 29 , wherein the composition further comprises a lipophilic compound selected from the group consisting of organic solvents, phosphatidyl cholines, cholesterols, and mixtures thereof.  
     
     
         33 . A method according to  claim 27 , wherein the step of administering is a dosing method selected from the group consisting of oral administering, parenteral administering, transdermal administering, subcutaneous injecting, intravenous injecting, intraperitoneal injecting, intramuscual injecting, intresternal injection, intrathecal injection, intraventricular injecting, intracerebroventricular injecting, and infusing.  
     
     
         34 . A method according to  claim 27 , wherein the composition is administered in a unitary dose of from about 1 mg to about 1000 mg.  
     
     
         35 . A method according to o  claim 34 , wherein the unitary dose is administered from about 1 to about 3 times a day.  
     
     
         36 . A method of treating a patient for acute lung injury comprising administering to the patient an effective antimicrobial amount of an antimicrobial lung surfactant protein compound selected from the group consisting of surfactant protein A and derivatives, analogs, homologs, salts and fragments thereof; surfactant protein D and derivatives, analogs, homologs, salts and fragments thereof; and mixtures thereof.  
     
     
         37 - 44 . (canceled)